賽托瑞醫療 CYTX 深 滬
等待開盤 06-25 09:30:00 美东时间
0.2077
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.2077
- 總市值 376.46万
- 52周最高 14062.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3825.00
- 委 比 0.00%
- 總股本 1812.50万
- 歷史最高 13865625.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 3825.00
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analyst ratings page.
06-08 21:52
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex June 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Allstate and Teleflex on Monday. HIGHLIGHTS * Adobe Inc ADBE.O : TD Cowen cuts target price to $285 from $310
06-08 16:01
Plus Therapeutics Launches New At-The-Market Equity Program
An announcement from Plus Therapeutics ( ($PSTV) ) is now available. On June 1,...
06-06 06:26
Plus Therapeutics Subsidiary's Clinical Laboratory Gets Accreditation From College Of American Pathologists
CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous
06-04 19:32
Plus Therapeutics Presents New Data On Health Economics Trial Evaluating Economic Impact Of Earlier Detection And Therapeutic Management Of LM Through CNSide Cerebrospinal Fluid Assay
Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today
05-26 19:35
Plus Therapeutics Partners With Ephemeral Technologies To Deliver Unique AI Execution Platform For CNS Oncology
Partnership to deliver a novel AI-native integrated CNS oncology platformPlatform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision
05-19 19:34
Plus Therapeutics Stockholders Back Directors and Incentive Plan
Plus Therapeutics ( ($PSTV) ) has shared an update. Plus Therapeutics, Inc. hel...
05-16 06:50
Plus Therapeutics Q1 EPS $(1.05) Misses $(0.85) Estimate, Sales $1.028M Beat $974.000K Estimate
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.85) by 23.53 percent. This is a 96.48 percent increase over losses of $(29.86) per share
05-16 04:10
Plus Therapeutics Subsidiary Gets Enrolled In Medicare Program, Receives Provider Transaction Access Number From Centers For Medicare & Medicaid Services
Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today
05-07 19:33
Why Is Plus Therapeutics Stock Gaining Friday?
Plus Therapeutics stock jumps after FDA grants Orphan Drug status to Reyobiq for pediatric brain cancer, boosting long-term outlook.
04-11 02:12
